Operational Efficiency Gains in Pharmacy

22 January 2026

MedPal AI plc

("MedPal AI" or the "Company")

Significant Operational Efficiency Gains in Pharmacy Subsidiary

MedPal AI plc (AIM: MPAL), the digital health and AI company, is pleased to announce that, following recent technology infrastructure upgrades, it has achieved a substantial improvement in dispensing efficiency within its wholly owned subsidiary MedPal Limited.

Operational Highlights

• 30-fold increase in dispensing efficiency achieved through server technology updates and upgrades; previously it took an hour to process 40 prescriptions, but with the update in place, the Robopharma robot is capable of processing more than 100 prescriptions in less than 5 minutes

• Enhanced capacity supports continued growth in pharmacy operations across NHS contracts and retail services

• Investment reinforces the Company's commitment to scalable, technology-driven healthcare delivery

The significant efficiency improvement has been realised through comprehensive server infrastructure modernisation within MedPal Limited, the Company's pharmacy operating subsidiary. This enhancement directly supports the Company's robotic dispensing capabilities and integrated pharmacy management systems.

Jason Drummond, CEO of MedPal AI plc, commented:

"This 30x improvement in dispensing efficiency demonstrates the operational leverage inherent in our pharmacy infrastructure. By investing strategically in server technology, we have dramatically enhanced our capacity to serve patients across our NHS contracts and retail pharmacy services. This upgrade positions MedPal Limited to handle significantly increased prescription volumes while maintaining the quality and reliability our customers expect.

"The technology upgrade supports the Company's broader strategy of integrating AI-powered healthcare services with regulated pharmacy operations, enabling efficient scaling across its care home and retail pharmacy divisions."

Enquiries:

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.